Top

Published in:

01-07-2009 | Gastrointestinal Oncology

Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Center

Authors: H. Richard Alexander Jr., MD, David L. Bartlett, MD, Steven K. Libutti, MD, James F. Pingpank, MD, Douglas L. Fraker, MD, Richard Royal, MD, Seth M. Steinberg, PhD, Cynthia B. Helsabeck, RN, Tatiana H. Beresneva, MD

Published in: Annals of Surgical Oncology | Issue 7/2009

Abstract

Aim

To define the indications for hyperthermic isolated hepatic perfusion (IHP) in patients with unresectable liver metastases (LM) from colorectal cancer (CRC) with particular focus on IHP’s utility as a second-line option for patients whose tumors have progressed following combination systemic chemotherapy treatment.

Methods

From June 1994 through July 2005, 120 patients with unresectable CRC LM underwent IHP with melphalan (n = 69), tumor necrosis factor (TNF) (n = 10) or both (n = 41). Hepatic arterial infusion (HAI) with floxuridine started 6–8 weeks post IHP in 46 (38%). Patients were followed for toxicity, radiographic response, and overall survival (OS). Wilcoxon rank-sum and Fisher’s exact tests were used to compare parameters by response category; survival and hepatic progression-free survival were calculated by the Kaplan–Meier method.

Results

Of 79 males and 41 females, 96 (80%) received prior chemotherapy. There were five (4%) operative/treatment mortalities. There were 69 responses in 114 evaluable patients (61%). Total melphalan dose and combination melphalan/TNF were each associated with response; age, preoperative carcinoembryonic antigen (CEA), prior chemotherapy for established LM, tumor burden, and post-IHP HAI therapy were not. Median overall survival was 17.4 months and 2-year survival was 34%. Factors found to be independently related to survival were preoperative CEA <30 ng/mL and use of post-IHP HAI (P < 0.015).

Conclusions

IHP results in marked tumor regression and prolonged survival in patients with CRC LM. Continued development of IHP in this clinical setting is warranted.

Stangl R, tendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.PubMedCrossRef

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24:3347–53.PubMedCrossRef

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.PubMedCrossRef

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluourouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059–69.PubMedCrossRef

Rothenberg ML. Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2004;4(1):S16–21.PubMedCrossRef

Grover A, Alexander HR, Jr. The past decade of experience with isolated hepatic perfusion. Oncologist. 2004;9:653–64.PubMedCrossRef

Alexander HR, Jr., Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12:138–44.PubMedCrossRef

Libutti SK, Bartlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000;191:519–30.PubMedCrossRef

Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176–87.PubMedCrossRef

10.

Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I–131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242–8.PubMedCrossRef

11.

Lans TE, Bartlett DL, Libutti SK, Gnant MFX, Liewehr DJ, Venzon DJ, et al. Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001;7:784–90.PubMed

12.

Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176–87.PubMedCrossRef

13.

Goldberg RM, Rothenberg ML, van CE, Benson AB, Ill, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38–50.PubMedCrossRef

14.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef

15.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.PubMedCrossRef

16.

Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhii SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243–9.PubMedCrossRef

17.

Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58–65.PubMedCrossRef

18.

Benoist S, Brouquet A, Penna C, Julie C, El HM, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.PubMedCrossRef

19.

Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.PubMedCrossRef

20.

Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol. 1954;30:969–85.PubMed

21.

Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly M. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer. 1987;59:1547–53.PubMedCrossRef

22.

Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416–24.PubMedCrossRef

23.

Posner MC, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995;1:274–80.PubMed

24.

Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 2002;100:1334–9.PubMed

25.

Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740–5.PubMedCrossRef

26.

Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Jr., Bodoky G, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008;26:4544–50.PubMedCrossRef

27.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004;22:4701–9.CrossRef

Title: Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Center
Authors: H. Richard Alexander Jr., MD
David L. Bartlett, MD
Steven K. Libutti, MD
James F. Pingpank, MD
Douglas L. Fraker, MD
Richard Royal, MD
Seth M. Steinberg, PhD
Cynthia B. Helsabeck, RN
Tatiana H. Beresneva, MD
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0482-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Analysis of Factors Associated with Outcome in Patients Undergoing Isolated Hepatic Perfusion for Unresectable Liver Metastases from Colorectal Center

Abstract

Aim

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases

Clinicopathological Factors and Nomograms Predicting Nonsentinel Lymph Node Metastases After Neoadjuvant Chemotherapy in Breast Cancer Patients

Caspase 9 and Caspase 8 Gene Polymorphisms and Susceptibility to Bladder Cancer in North Indian Population

Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer

Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.